IHT Wealth Management LLC increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 2.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,082 shares of the company’s stock after purchasing an additional 283 shares during the quarter. IHT Wealth Management LLC’s holdings in Eli Lilly And Co were worth $1,676,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Eli Lilly And Co in the fourth quarter valued at approximately $1,171,509,000. Jennison Associates LLC lifted its stake in Eli Lilly And Co by 125.9% in the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after buying an additional 5,679,574 shares in the last quarter. BlackRock Inc. grew its holdings in Eli Lilly And Co by 5.6% during the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after buying an additional 3,420,265 shares during the last quarter. Capital International Investors increased its position in Eli Lilly And Co by 3.6% during the fourth quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock worth $3,424,531,000 after buying an additional 910,672 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Eli Lilly And Co by 6.7% in the fourth quarter. FMR LLC now owns 14,235,227 shares of the company’s stock worth $1,870,935,000 after acquiring an additional 888,413 shares during the last quarter. Institutional investors own 77.44% of the company’s stock.
A number of analysts recently commented on the company. Morgan Stanley cut Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research report on Sunday, April 19th. Mizuho upped their price objective on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Barclays initiated coverage on shares of Eli Lilly And Co in a research report on Thursday, February 27th. They set an “overweight” rating on the stock. Cfra boosted their price target on Eli Lilly And Co from $146.00 to $167.00 and gave the company a “hold” rating in a report on Friday, April 24th. Finally, Goldman Sachs Group upgraded Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price objective on the stock in a report on Wednesday, March 11th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $158.64.
In other Eli Lilly And Co news, SVP Stephen F. Fry sold 14,657 shares of the business’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $134.30, for a total value of $1,968,435.10. Following the transaction, the senior vice president now owns 110,572 shares in the company, valued at approximately $14,849,819.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 12,663 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $163.60, for a total transaction of $2,071,666.80. Following the completion of the transaction, the insider now directly owns 112,197,641 shares of the company’s stock, valued at $18,355,534,067.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 906,320 shares of company stock valued at $132,984,238. Insiders own 0.09% of the company’s stock.
Eli Lilly And Co stock traded down $0.72 during midday trading on Tuesday, reaching $151.73. The stock had a trading volume of 65,676 shares, compared to its average volume of 3,140,893. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $164.90. The stock has a market capitalization of $146.29 billion, a PE ratio of 25.24, a price-to-earnings-growth ratio of 1.83 and a beta of 0.24. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s 50-day simple moving average is $154.63 and its 200 day simple moving average is $137.89.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The company had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same period in the previous year, the firm earned $1.33 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 15.1% on a year-over-year basis. Equities analysts predict that Eli Lilly And Co will post 6.81 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $0.74 dividend. The ex-dividend date of this dividend is Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.95%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 49.01%.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: What is a stock split?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.